Small molecule modulators of IL-17

A compound according to formula (I)

• wherein:
• R1 is selected from the group consisting of 5- or 6-membered heteroaryl, 9- or 10-membered bicyclic heteroaryl, phenyl, (C1-C6)alkoxy, (C3-C7)cycloalkoxy, (C1-C6)alkyl, phenyl-(C1-C4)alkyl, (C3-C7)cycloalkyl, 4-6-membered heterocycloalkyl, and —NRcRd, wherein the 5- or 6-membered heteroaryl, 9- or 10-membered bicyclic heteroaryl, phenyl, (C1-C6)alkoxy, (C3-C7)cycloalkoxy, (C1-C6)alkyl, phenyl-(C1-C4)alkyl, (C3-C7)cycloalkyl, and 4-6-membered heterocycloalkyl is optionally substituted with one or more substituents independently selected from Ra;
• Ra is selected from the group consisting of deuterium, halogen, hydroxy, —NRcRd, (C1-C6)alkyl, (C1-C6)alkylcarbonyl, (C3-C7)cycloalkyl, phenyl, 5- or 6-membered heteroaryl, and 4-6-membered heterocycloalkyl, wherein the (C1-C6)alkyl, (C1-C6)alkylcarbonyl, (C3-C7)cycloalkyl, phenyl, 5- or 6-membered heteroaryl, or 4-6-membered heterocycloalkyl is optionally substituted with one or more substituents independently selected from deuterium, halogen, hydroxy, cyano, (C1-C4)alkyl, (C3-C7)cycloalkyl, (C1-C4)alkoxy, —SO2—(C1-C4)alkyl, and —NRcRd;
• R2 is a 5- or 6-membered heteroaryl, wherein the 5- or 6-membered heteroaryl is optionally substituted with one or more substituents independently selected from Rb, wherein the 5- or 6-membered heteroaryl may optionally contain —CO— as a ring member, and wherein when the 5 membered heteroaryl contains nitrogen as a ring atom that may optionally be substituted with a substituent selected from R8;
• Rb represents is selected from the group consisting of deuterium, halogen, cyano, hydroxy, —NRcRd, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkyl-CO—O—(CH2)n—, and (C3-C7)cycloalkyl, wherein n is 1-4, and wherein the (C1-C6)alkyl, (C1-C6)alkoxy, or (C3-C7)cycloalkyl is optionally substituted with one or more substituents independently selected from deuterium, halogen, cyano, hydroxy, —NRcRd, and (C1-C4)alkoxy;
• Rc and Rd each independently are hydrogen or (C1-C6)alkyl, or Rc and Rd together form pyrrolidinyl or piperidinyl, wherein the (C1-C6)alkyl, pyrrolidinyl, or piperidinyl is optionally substituted with one or more substituents independently selected from halogen, cyano, and hydroxy;
• R8 is -L-PO(OH)2 or —CHRgO—(CO-A-NRh)m—CO-A-NRhRi;
• L is a bond or —CHRgO—;
• m is 0 or 1;
• each —CO-A-NRh— independently is a natural D-form amino acid residue, a natural L-form amino acid, or a mixture thereof, wherein the amino acid residue may optionally be substituted on the α-amino group with a substituent Rh;
• Rg, Rh, and Ri each independently are hydrogen or (C1-C6)alkyl;
• R3 is selected from the group consisting of hydrogen, deuterium, hydroxy, and halogen;
• R4 is selected from the group consisting of hydrogen, deuterium, and halogen;
• R5 is selected from the group consisting of —CHR6R7, (C3-C10)cycloalkyl, and G, wherein the (C3-C10)cycloalkyl and G are optionally substituted with one or more substituents independently selected from deuterium, halogen, cyano, hydroxy, (C1-C4)alkyl, and halo(C1-C4)alkyl;
• G is selected from the group consisting of G1, G2, and G3
• R6 and R7 each independently are selected from the group consisting of hydrogen, phenyl, (C1-C6)alkyl, and (C3-C7)cycloalkyl, wherein the phenyl, (C1-C6)alkyl, or (C3-C7)cycloalkyl is optionally substituted with one or more substituents independently selected from halogen, cyano, hydroxy, and (C1-C4)alkyl, with the proviso that at least one of R6 and R7 are different from hydrogen;
• provided that when R5 is (C2-C4)alkyl, cyclopentyl, cyclohexylmethyl, benzyl, or substituted benzyl, R1 is selected from the group consisting of pyrazolyl, imidazolyl, thiazolyl, isoxazolyl, and triazolyl, wherein the pyrazolyl, imidazolyl, thiazolyl, isoxazolyl, or triazolyl is optionally substituted with one or more substituents independently selected from Ra;
• or a pharmaceutically acceptable salt, hydrate, or solvate thereof.